Liraglutide in the treatment of patients with diabetes mellitus type 2

"Glucagon-like peptide-1" (GLP-1) receptor agonists have found their way into the arsenal of treatments of diabetes mellitus type 2. Liraglutide is a GLP-1 analogue administered only once daily. It has been demonstrated in phase III studies to reduce the glycosylated hemoglobin (HbA 1c) level in all diabetic patients (from monotherapy to a combination therapy with oral antidiabetics) by an average of 1% to 1,5% without increasing the risk of hypoglycemia. On top of this improved glycemic control, patients also showed an average weight loss of 2 to 3 kg. Clinical trials produced a number of interesting findings which exceed pure simple beta-cell effects, such as an improved blood pressure and beneficial effects on indirect cardiovascular markers. In addition, studies in preclinical models indicate a potential improvement in beta-cell function. The main side-effect reported is transient nausea. Liraglutide is currently reimbursed in Belgium for patients who suffer from diabetes mellitus type 2 and do not obtain a sufficient glycemic control with an oral therapy of combined metformin and sulfonylurea.

Jaar van publicatie:2012